There is growing bipartisan support for taking action, and CPA is proud to join with more than two dozen organizations representing thousands of voices that support closing the de minimis loophole.
The Coalition to Close the De Minimis Loophole launched today, representing thousands of voices, from the families of victims of fentanyl fatalities and nonprofit and nonpartisan organizations to labor unions, domestic law enforcement associations, domestic manufacturers, and business associations.
America’s largest generic drug supplier, Aurobindo, is riddled with safety and quality issues, including ties to overseas suppliers with links to China’s military.
The RSC bill sends a strong message to lawmakers like Financial Services Committee Chairman Patrick McHenry, who has consistently done the bidding of Wall Street and the CPP.
Wolfe told the Commissioners on Monday that he doubts countries will be able to tolerate the deluge of China exports, adding that he sees no end in sight to this onslaught for the time being.
Three Southeast Asian nations have become China’s “Mini Me” when it comes to the solar supply chain.
The roughly 485 million packages that come into the U.S. duty free via the de minimis loophole is “overwhelming” and that volume “makes it harder for us to police products for consumer safety,” James Joholske, director of the office of import surveillance at the U.S. Consumer Product and Safety Commission (CPSC) told the U.S. China Economic and Security Review Commission on March 1
Roughly 40 congressional staff members had a chance to meet with and hear from industry leaders as diverse as Florida farmers to multinational corporations in the renewable energy space about the trials and tribulations of competing with emerging markets that play by different rules. And often break existing ones.
China’s predatory auto industry is a direct threat to American auto manufacturers and the hundreds of thousands of hard-working men and women that rely on this critical industry.
Coalition vice presidents explain the FDAs shortcomings and why U.S. medicines are often in short supply in a new American Affairs Journal article.
